Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 3 - Drugs for disorders of the metabolism
Patents for A61P 3 - Drugs for disorders of the metabolism (129,789)
02/2003
02/26/2003EP0969827B1 Mixture of primary fatty acids obtained from sugar cane wax
02/26/2003EP0944396B1 Compositions and methods for enhancing intestinal function
02/26/2003EP0822986B1 Antagonists of human interleukin-6 that are totally incapable of binding gp 130, and their use in the preparation of pharmaceutical compounds
02/26/2003CN1399678A Human Enzymes of metalloprotease family
02/26/2003CN1399646A Recombinant fusion molecules
02/26/2003CN1399644A Novel human G-Protein coupled receptor
02/26/2003CN1399636A Adenosine receptor antagonists and methods of making and using the same
02/26/2003CN1399633A 嘧啶衍生物 Pyrimidine derivatives
02/26/2003CN1399631A Novel hydantoin, thiohydantoin, pyrimidinedione and thioxopyrimidinone derivatives, preparation method and use as medicines
02/26/2003CN1399630A Substituted 1,2,3,4,5,6-hexahydro-2,6-methano-3-benzazocines and the use thereof as medicaments
02/26/2003CN1399559A Micro-cluster liquids and methods of making and using them
02/26/2003CN1399557A Remedies for drug-resistant hypercalcemia
02/26/2003CN1399549A Ultrafinel-carnitine, methods of preparing the same, compositions containing the same, and methods of using the same
02/26/2003CN1399541A Colloidal suspension of submicronic particles as vectors for active principles and method for preparing same
02/26/2003CN1399520A Phytosterol and phytostanol compositions
02/26/2003CN1398898A Extraction and separation process of ash tree flower sporophore polyglycopeptide
02/26/2003CN1398896A Hybrid peptide with vascularization inhibiting activity
02/26/2003CN1398838A Diphenylethylene compound and its prepn and application in preventing and treating diabetes
02/26/2003CN1398632A Blood fat-regulating medicine composition
02/26/2003CN1398630A Active largehead atractylodes saccharide complex for reducing blood sugar and its prepn and use
02/26/2003CN1398615A Chinese medicine prepn for treating fatty liver and obesity
02/26/2003CN1102067C Process for extracting active iodine from kelp
02/26/2003CN1102065C Linolenic acid soft capsule and production process thereof
02/26/2003CN1102061C Enqlish yew-manna tea
02/26/2003CN1102055C Medicine for curing diabetes and its preparation method
02/25/2003US6525241 Expression methods
02/25/2003US6525220 Intermediates for the synthesis of benzimidazole derivatives and a process for the preparation thereof
02/25/2003US6525206 Compounds with high monoamine transporter affinity
02/25/2003US6525202 Cyclic amine phenyl beta-3 adrenergic receptor agonists
02/25/2003US6525199 Ring coupling, reduction and deprotecting; synthesis of compounds for alleviation and treatment of symptoms due to ischemic diseases
02/25/2003US6525196 5HT1 antagonists for antidepressant therapy
02/25/2003US6525184 Self-regulated apoptosis of inflammatory cells
02/25/2003US6525178 PGC-1, a novel brown fat PPARgamma coactivator
02/25/2003US6525093 Compounds to treat diabetes and associated conditions
02/25/2003US6525089 Pharmaceutical composition containing decursin
02/25/2003US6525083 Antidiabetic agents, antilipemic agents, anticholesterol agents
02/25/2003US6525080 Thiazoline acid derivatives
02/25/2003US6525075 Antidepressant azaheterocyclylmethyl derivatives of 7,8-dihydro-1,6,9-trioxa-3-aza-cyclopenta[a]naphthalene
02/25/2003US6525072 Prevention and treatment of cellular disorders such as cancer
02/25/2003US6525070 Bipiperidine derivatives as modulators of CCR3 activity and as H1 antagonists
02/25/2003US6525067 Substituted heterocyclic derivatives
02/25/2003US6525052 Compounds useful as reversible inhibitors of cysteine proteases
02/25/2003US6525051 For treating cytokine-induced hypotension, inflammatory bowel disease, cerebral ischemia, arthritis, adult respiratory distress syndrome, asthma
02/25/2003US6525048 Aminomethylphenoxymethyl/benzisoxazole substituted azabicyclic compounds; depression, generalized anxiety disorder, obesity, migraine; 2-(5-Fluoro-benzo(d)isoxazol-3-y)-7-(3-morpholin-4-ylmethylphenoxymethyl) -octahydro-pyrido(1,2-a)pyrazine;
02/25/2003US6525047 Which are growth hormone secretogogues and increase the level of endogenous growth hormone; treating osteoporosis, congestive heart failure, frailty associated with aging, obesity; accelerating bone fracture repair
02/25/2003US6525025 Controlling apoptosis; cardiovascular disorders; central nervous system disorders
02/25/2003US6524613 Hepatocellular chimeraplasty
02/21/2003WO2002016354A1 Chromenone derivatives and their use for treating diseases in conjunction with 5-hta1 receptors and/or dopamine d2 receptors
02/21/2003WO2002016328A1 Biphenyl derivatives and the use thereof as integrin inhibitors
02/21/2003CA2420208A1 Biphenyl derivatives and their use as integrin inhibitors
02/21/2003CA2420206A1 Chromenone derivatives and the use thereof for the treatment of diseases in connection with 5-hta1 receptors and/or dopamine d2 receptors
02/20/2003WO2003014703A2 Nucleic acids, polypeptides, single nucleotide polymorphisms and methods of use thereof
02/20/2003WO2003014702A2 Uses of mammalian cytokine; related reagents
02/20/2003WO2003014342A2 Identification of a dna variant associated with adult type hypolactasia
02/20/2003WO2003014318A2 Methods for treating diabetes and other blood sugar disorders
02/20/2003WO2003014307A2 Antisense modulation of apolipoprotein(a) expression
02/20/2003WO2003014294A2 Tacis and br3 polypeptides and uses thereof
02/20/2003WO2003014145A2 Peptides that bind to atherosclerotic lesions
02/20/2003WO2003014125A1 Therapeutically useful tetracyclic ligands
02/20/2003WO2003014124A1 Substituted 5,6,6a,11b-tetrahydro-7-oxa-5-aza-benzo[c]fluorene-6-carboxylic acid derivatives serving as nmda antagonists
02/20/2003WO2003014118A1 THERAPEUTIC 1H-PYRIDO[4,3-b]INDOLES
02/20/2003WO2003014114A2 Substituted amine derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
02/20/2003WO2003014098A1 Arylpiperazines and arylpiperidines and their use as metalloproteinase inhibiting agents
02/20/2003WO2003014097A1 Arylsulfonyl derivatives with 5-ht6 receptor affinity
02/20/2003WO2003014092A1 Arylpiperazines and arylpiperidines and their use as metalloproteinase inhibiting agents
02/20/2003WO2003014085A1 Solvates of lercanidipine hydrochloride and new crystalline forms of lercanidipine hydrochloride
02/20/2003WO2003014083A1 Spiro compounds
02/20/2003WO2003014082A1 Cyclopenta ` b ! indole derivatives as spla2 inhibitors
02/20/2003WO2003014073A1 Fatty acid compounds, preparation and uses thereof
02/20/2003WO2003013655A2 Carbonic anhydrase inhibitors
02/20/2003WO2003013608A1 ORAL PHARMACEUTICAL COMPOSITION CONTAINING A COMBINAITION OF PPARα AND A HMG-COA REDUCTASE INHIBITOR
02/20/2003WO2003013607A1 ORAL PHARMACEUTICAL COMPOSITION CONTAINING A COMBINATION OF FENOFIBRATE AND A HMG-CoA REDUCTASE INHIBITOR
02/20/2003WO2003013604A2 Migenix agonists and antagonists for use in the treatment of metabolic disorders
02/20/2003WO2003013585A1 Mifaxin agonists and antagonists for use in the treatment of metabolic
02/20/2003WO2003013584A1 Xafinix agonists and antagonists for use in the treatment of metabolic disorders
02/20/2003WO2003013583A1 Faxigen agonists and antagonists in the treatment of metabolic disorders
02/20/2003WO2003013582A1 Genoxit agonists and antagonists for use in the treatment of metabolic disorders
02/20/2003WO2003013581A1 Agonists and antagonists of genceptin for the treatment of metabolic disorders
02/20/2003WO2003013580A1 Tr xidatin agonists and antagonists treatment of metabolic disorders
02/20/2003WO2003013579A1 Lypergix agonists and antagonists for use in the treatment of metabolic disorders
02/20/2003WO2003013578A1 Omoxin agonists and antagonists for use in the treatment of metabolic disorders
02/20/2003WO2003013574A1 Melanin-concentrating hormone antagonists
02/20/2003WO2003013569A2 Use of thrombin-derived peptides for the therapy of chronic dermal ulcers
02/20/2003WO2003013566A1 High molecular weight, lipophilic, orally ingestible bioactive agents in formulations having improved bioavailability
02/20/2003WO2003013563A2 Mineral-protein preparations (mpp) and neuropathies in diabetes
02/20/2003WO2003013562A1 Artichoke leaf extracts
02/20/2003WO2003013559A1 Bile acid absorbent/adsorbent
02/20/2003WO2003013550A1 Micronutrient phosphates as dietary and health supplements
02/20/2003WO2003013546A1 Hypoglycemic agent
02/20/2003WO2003013542A1 Asymmetric synthesis of kavalactones
02/20/2003WO2003013539A1 Neuroprotective drug
02/20/2003WO2003013532A1 Chiral dinapsoline
02/20/2003WO2003013530A2 Salts of substituted 1, 2, 3, 4-tetrahydroquinoline-2-carboxylic acid derivatives as nmda antagonists
02/20/2003WO2003013529A1 Paroxetine glycyrrhizinate
02/20/2003WO2003013513A1 Stable emulsion composition
02/20/2003WO2003013512A2 Crystalline forms of fluvastatin sodium
02/20/2003WO2003013510A1 3-arylsulfonyl-7-piperazinyl- indoles, -benzofurans and -benzothiophenes with 5-ht6 receptor affinity for treating cns disorders
02/20/2003WO2003013509A1 N-phenylpyrrole guanidine derivatives as melanocortin reception ligands
02/20/2003WO2003013501A1 Improved pharmaceutical composition containing a ppar alpha agent and a process for preparing it
02/20/2003WO2003013500A1 Improved pharmaceutical composition containing a ppar alpha agent and a process for preparing it
1 ... 927 928 929 930 931 932 933 934 935 936 937 938 939 940 941 942 943 944 945 946 947 ... 1298